•October 2017: AkornChairman of the Board, John Kapoor, was arrested and charged with leading a scheme to bribe doctors to prescribe Subsys, a form of the prescription opioid drug fentanyl. Kapoor and other executives also were charged with defrauding and misleading health insurers that were reluctant to approve payment for the drug when it was prescribed for non-cancerpatients. •November 2017: John Kapoor, stepped down as Akorn’s, Chairman of the Board •Feb 2018: Freseniusannounced that the company may back out of the planned acquisition if a probe it was conducting into data integrity at Akornyielded evidence of wrongdoing. Fresenius had received information from an anonymous source alleging deficiencies and misconduct relating to product development at the generic drugmaker. •March 2018: Akorn said in court documents it investigated the possible submission of falsified data and fired an executive who was involved. Despite announcing the firing; the executive (Mark Silverberg) was suspended and given a consulting position with a $250,000 salary. He stands to receive a payout if the merger is consummated, according to the filing. The executive’s name was blacked out in the filing. •March 2018: Akorn Settles US SEC Claims stemming from inaccurate financial statements issued in 2014 that it later needed to restate. Akorn, former Chief Financial Officer,Timothy Dick and former Controller,DavidHebedaagreed to settle a lawsuit filed in federal court in Chicago. Dick and Hebedaeach agreed to pay a $20,000 penalty without admitting or denying wrongdoing. •April 2018: Fresenius said it had decided to pull out of its planned acquisition of Akornafter it found data integrity breaches at the U.S. generic drug maker. •May: 2018: Fresenius alleged it uncovered “blatant fraud at the very top level” of U.S. generic drugmaker Akorn. •July 2018: Court date is set for July 9th (Delaware): Akorn v. Fresenius KabiAG, No. 2018-0300, Delaware Chancery Court (Wilmington). •October 2018: John Kapoor trial date Among the above, internally process are flawed and deliberately ignored. Executives receiving kickbacks. Email: OFCCP-MW-CC4@dol.gov if you have been illegally discriminated in any way by Akorn.
gets better https://finance.yahoo.com/m/20f3ce2d-d071-360f-ba41-79a83d0a18a7/akorn-was-warned-about.html?.tsrc=applewf
Ohhh, a consultant told Akorn where they have deficiencies, big deal, that's why they were hired. Old news, nothing to see here... move along.
Keeps getting better.., love how employees try to down play... it’s the individual circumstance.... it’s the trending history.... https://finance.yahoo.com/m/bd32429e-7338-3f6d-8d67-2feebc776960/lax-drugmaker-computer.html?.tsrc=applewf
No other person in Akorn is more unethical and non-compliant or as Trump would call it "Crooked.." as BL is. Being fakely charming in Akorn is more important than being ethical/compliant. Thank God MS is gone!
Couldn't agree more! They are grabbing at straws. Culture is at it's worst with no change in sight than for worse. They gonna lie and fraud their way to bankruptcy and liquidation
Akorn is continuing to wilfully deceive FDA even after all the extensive and historically trending fraudulent history. They are begging for more whistleblowers
https://www.forbes.com/sites/michelatindera/2018/12/07/fentanyl-billionaire-no-more-john-kapoors-net-worth-drops-below-1-billion/#324ae93b9035
No kidding. And if you don't smell back their butt, you are ostracized. In Akorn, if you are not screwing the company for the long term by fudging everything, you are not a good employee, that's how bad HR, hiring process and quality has become.
Why does QMCAP has a fraudulent person ? This person doesn't know anything about quality nor has any analytical skill but to butt in just to act like a secretary to pander and seek recognition. QMCAP would be better served having Silverberg than this person. Beware of this far worse virulent agent than Silverberg ever could be. You make and save money by weeding out unqualified people like this person.
Gotta start somewhere and everywhere. Akorn can't afford to procastinate to fix products, process and people issues
With the new re-org, it's funny, shocking and appalling , to watch least one direct report taking steps to go under Kim's umbrella from Jaime's (under Keith's per previous structure) CONFLICT OF INTEREST IS WRITTEN ALL OVER IT. BUT THATS NOTHING NEW IN AKORN.
